HUGE NEWS! (OF FURTHER CONFIRMATION TYPE)
HNAB realizing the purposes of a publically traded company, raising money to fund a VIABLE, PIONEERING PRODUCT in multi-billion dollar industry... HNAB is steps away from having it on the shelf...!
--------------------------------------------
Hana Biosciences Incorporated (HNAB) engages in the biotechnological development and commercialization of cancer therapies to enhance efficacy to current standard-of-care protocols for the treatment of various cancers. The Company presently has four drug candidates under development, including Marqibi ®, Menadione Topical Lotion, Brakiva (TM) and Alocrest (TM).
In the report, the analyst notes:
"As of September 30, the Company's drug candidate Marqibo is in phase II for the treatment of metastatic uveal melanoma. The Company achieved its target enrollment in 2009, with plans for a confirmatory trial of the drug in 2011 and intentions to file for a New Drug Applications (NDA) with the Food and Drug Administration (FDA) in 2010. Further progression toward commercialization of Marqibo is dependent upon pending results of phase II studies.
"The Company expects to report an additional $5.0 million of expenses related to Marqibo in its coming fourth-quarter earnings report. In its latest 10-Q filing in October, the Company said it needs an additional $8.0 million for an accelerated approval of Marqibo and $45.0 million for full FDA approval. Marqibo is expected to undergo three to four more years of development and FDA approval time before the Company can embark with commercialization of the product."
AI
